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Most anticancer drugs are greatly limited by the serious side eﬀects that they cause. Doxorubicin (DOX) is an antineoplastic
agent, commonly used against breast cancer. However, it may lead to irreversible cardiotoxicity, which could even result in
congestive heart failure. In order to avoid these harmful side eﬀects to the patients and to improve the therapeutic eﬃcacy of
doxorubicin, we developed DOX-loaded polyethylenimine- (PEI-) enhanced human serum albumin (HSA) nanoparticles. The
formed nanoparticles were ∼137nm in size with a surface zeta potential of ∼+15mV, prepared using 20µgo fP E Ia d d e dp e r
mg of HSA. Cytotoxicity was not observed with empty PEI-enhanced HSA nanoparticles, formed with low-molecular weight
(25kDa) PEI, indicating biocompatibility and safety of the nanoparticle formulation. Under optimized transfection conditions,
approximately 80% of cells were transfected with HSA nanoparticles containing tetramethylrhodamine-conjugated bovine serum
albumin. Conclusively, PEI-enhanced HSA nanoparticles show potential for developing into an eﬀective carrier for anticancer
drugs.
1.Introduction
Doxorubicin (Adriamycin) is a commonly used anti-cancer
drug. It is most often used against breast and esophageal
carcinomas, osteosarcoma and soft-tissue sarcomas, and
Hodgkin’sandnon-Hodgkin’slymphomas[1].Theeﬀective-
ness of doxorubicin (DOX) in treating various types of can-
cers is greatly limited by the serious side eﬀects caused by the
drug.TheinitialsideeﬀectscausedasaresultofDOXadmin-
istrationincludelessserioussymptoms,suchasnausea,vom-
iting, myelosuppression, and arrhythmia, which are usually
reversible [1]. However, DOX-associated cardiomyopathy
andcongestiveheartfailurehaveraisedgraveconcernamong
health practitioners [2]. A widely researched approach of
increasing the eﬃcacy, while lowering the deleterious side
eﬀectscausedbyanti-canceragentssuchasdoxorubicin,isof
developing nanoparticle-based drug delivery systems [3–5].
Various kinds of nanoparticles have been studied for
thedeliveryofDOX,whichincludepoly(butylcyanoacrylate)
[6], poly(isohexylcyanoacrylate) [7], poly(lactic-co-glycolic
acid [8], chitosan [9], gelatine [10], and liposomes [11]).
In addition, Dreis et al. employed human serum albumin
(HSA) nanoparticles of a size range between 150 and
500nm to deliver DOX to a neuroblastoma cell line [3].
These nanoparticles showed a loading eﬃciency of 70–95%
and an increased anti-cancer eﬀe c ta sc o m p a r e dt of r e e
DOX. The endogenous HSA serves as a suitable material
for nanoparticle formation as albumin is naturally found
in the blood and is thus easily degraded, nontoxic, and
nonimmunogenic [12]. Albumin is an acidic protein and
remains stable between pH range 4–9 and temperatures up
to 60◦C. In addition, clinical studies carried out with HSA
particle formulations, Albunex [13] and Abraxane [14], have
shown that albumin-based nanoparticles do not have any
adverse eﬀects on the body.
Furthermore, albumin-based nanoparticle delivery sys-
tems are easily accumulated in tumor tissue due to the en-
hanced permeability and retention (EPR)eﬀect[15–17]. The
vasculature in an active tumor is diﬀerent from the vessels
found in normal tissue. The distinctive tumor vasculature2 Journal of Drug Delivery
has the following properties: hypervasculature, poorly devel-
oped vascular architecture, a defective lymphatic drainage,
and slow venous blood return [15, 16]. These characteristics
lead to the preferential accumulation and retention of mac-
romolecules and nanoparticles in the tumor tissue. There-
fore, using a nanoparticle delivery system to deliver low-
molecular-weightanti-cancerdrugswillbepassivelytargeted
tothetumourtissuethroughtheEPReﬀect[17].Inaddition,
studies have also suggested that accumulation of albumin-
based nanoparticles within the tumor tissue is also because
of transcytosis, which occurs by the binding of albumin
to 60-kDa glycoprotein (gp60) receptor, which then results
in the binding of gp60 with caveolin-1 and the conse-
quent formation of transcytotic vesicles [12, 18]. Taking into
consideration the factors mentioned above, HSA seems to be
a suitable material to use for nanoparticle synthe-sis.
The surface properties of nanoparticles play a vital role
in the cellular internalization of the particles. A neutrally
charged surface does not show tendency of interacting with
cell membranes, while charged groups found on nanopar-
ticles are actively involved in nanomaterial-cell interaction
[19]. Cho and Caruso found in their study of cellular inter-
nalizationofgoldnanoparticlesthatpositivelychargedparti-
clesdemonstrategreateradherencetothecellmembraneand
are thus taken up by the cells more than negatively and neu-
trally charged nanoparticles [20]. Cationic nanoparticles are
showntobindthenegativelychargedfunctionalgroups,such
as sialic acid, found on cell surfaces and initiate translocation
[19]. Due to the highly eﬃcient transfection property of
positively charged nanoparticles, many nanoparticle-based
drug and gene delivery systems are positively charged. In this
study,poly(ethylenimine)(PEI),acationicpolymer,hasbeen
used to coat the HSA nanoparticles in order to add stability
and a positive surface charge to the nanoparticles. PEI
may possess a linear or branched structure, with molecular
weight ranging between 1 and 1000kDa [21]. Typically,
branched low-molecular-weight PEI (<25kDa) has been
observed to result in higher cellular uptake. As shown in
our previous study, higher-molecular-weight PEI (70kDa)
leads to more cytotoxicity than lower-molecular-weight PEI
(25kDa) [22]. The most commonly used stabilizing agent
for the preparation of HSA nanoparticles, glutaraldehyde,
has been reported to interfere with the release of the encap-
sulated material [10, 23]. Thus, PEI is being employed as an
alternative to glutaraldehyde in the current study.
PEI has been previously used to stabilize HSA nanopar-
ticles. Initially, HSA nanoparticles stabilized using PEI were
studied as vectors for protein delivery [24]. The osteoinduc-
tive growth factor, bone morphogenetic protein-2 (BMP-2),
was encapsulated using PEI-coated albumin nanoparticles,
and results showed that the bioactivity of the BMP-2 was
retained, suggesting that the developed nanoparticles, are
promising vectors for systemic protein administration [24].
In addition, Zhang et al. showed that the encapsulation ef-
ﬁciency of BMP-2 using PEI-coated albumin nanoparticles
was >90% [25]. Furthermore, the eﬃcacy of PEI-coated
albumin nanoparticles for the delivery of BMP-2 was also
conﬁrmed in vivo with rats [26]. More recently, we showed
that PEI-coated HSA nanoparticles were promising vectors
for siRNA delivery [22].
In the current research study, the eﬀectiveness of
DOX-loaded polyethylenimine- (PEI-) enhanced HSA
nanoparticles used against MCF-7 breast cancer cells was
investigated. We prepared the nanoparticles using an
ethanol desolvation method and characterized by measuring
particle size, surface zeta potential, and cellular uptake
[22, 27, 28]. The cytotoxicity of the developed DOX-loaded
nanoparticles was assessed in comparison to free DOX at
varying drug concentrations over diﬀerent time points.
Results were promising and suggest that the study needs
to be followed up with an in vivo investigation of the
DOX-loaded PEI-enhanced HSA nanoparticles (Figure 1).
2.MaterialsandMethods
2.1. Materials. H u m a ns e r u ma l b u m i n( H S Af r a c t i o nV ,
purity 96–99%), 8% glutaraldehyde, and branched polyeth-
ylenimine (PEI) (MW ∼ 25,000) were purchased from
Sigma Aldrich (ON, Canada). Doxorubicin hydrochloride
was purchased from Calbiochem (Gibbstown, USA). All
other reagents were purchased from Fischer (ON, Canada).
Tetramethylrhodamine-conjugated bovine serum albumin
(BSA) was purchased from Invitrogen (ON, Canada). To
maintain the cell culture, the reagents such as fetal bo-
vine serum, trypsin, Dulbecco’s modiﬁed Eagle’s Medium
(DMEM), and Opti-MEM I Reduced Serum Medium were
obtained from Invitrogen (ON, Canada). The breast cancer
cell line, MCF-7, was purchased from ATCC (ON, Canada).
Promega Cell-Titer 96 AQueous Non-Radioactive Cell Pro-
liferation MTS Assay kit was purchased from Promega (Wis,
USA).
2.2. Cell Culture. MCF-7 cells were cultured on tissue
culture plates as per the manufacturer’s instructions. MCF-
7 cells were grown in Dulbecco’s modiﬁed Eagle’s Medium
(Invitrogen) supplemented with 10% (v/v) fetal bovine
serum (FBS) and placed in an incubator with 5% CO2 at
37◦C. The cells used in the experiments were obtained from
passages 5-6.
2.3. Preparation of DOX-Loaded PEI-Enhanced HSA Na-
noparticles. PEI-coated HSA nanoparticles were prepared at
room temperature using an ethanol desolvation technique
[22, 27–29]. In brief, 20mg of HSA was added to 1mL
of 10mM NaCl (aq) under constant stirring (800rpm) at
room temperature. The solution was stirred for 10min.
After total dissolution, the solution was titrated to pH 8.5
with 1N NaOH (aq) and stirred for 5min. This aqueous
phase was desolvated by the dropwise addition of ethanol
to aqueous HSA solution under constant stirring. Ethanol
was added until the HSA solution became turbid (∼1-
2mL). Cross-linking agent, 8% glutaraldehyde, was added to
form stable HSA particles. The obtained nanoparticles were
centrifuged three times and washed with deionized water
(dH20 ) ,f o l l o w e db yr e s u s p e n s i o ni na ne q u a lv o l u m eo f
PBS. PEI dissolved in dH20 was added to the nanoparticleJournal of Drug Delivery 3
preparationtoallowPEItoformanoutercoatingduetoelec-
trostatic binding. For the preparation of drug-loaded HSA
nanoparticles, doxorubicin was added to 1mL HSA solution
after pH adjustment and allowed to stir for 4hrs, followed
by ethanol addition. To determine the drug encapsulation
eﬃciency, an indirect method was employed as shown by
Sebak et al. [27]. The unloaded drug was quantiﬁed by
measuring the free drug found in the supernatant of the
prepareddrug-loadednanoparticles,usingaUVspectropho-
tometer. Using the amount of unloaded drug, the drug-
loaded quantity was determined (Total drug added (µg)—
free drug). The encapsulation eﬃciency was then calculated
using the amount of drug loaded into the nanoparticles:
amount of drug loaded (µg)/theoretical maximum drug
loading (µg) [8].
2.4. Puriﬁcation of PEI-Enhanced HSA Nanoparticles. PEI-
coated HSA nanoparticles were ultracentrifuged (16500g)
for 12min and added to 10mM NaCl (aq) by vortexing and
ultrasonication (Branson 2510). This method was repeated
thrice to ensure complete removal of impurities.
2.5. Determining Particle Size and Surface Zeta Potential.
The particle size and zeta potential were measured by elec-
trophoreticlaserDoppleranemometry,usingazetapotential
analyzer (Brookhaven Instruments Corporation, USA). The
nanoparticles were diluted 1:15 with distilled water prior to
measurement [27].
2.6. Surface Characterization of PEI-Enhanced HSA Nanopar-
ticles. The size and shape of the HSA nanoparticles were
observed by transmission electron microscopy (TEM), using
Philips CM200 200kV TEM (Markham, Canada). The
samples for TEM were prepared by ultracentrifuging the na-
noparticles and washing with distilled water, followed by air
drying the samples overnight to allow removal of moisture
[22, 27, 29].
2.7. Transfection of MCF-7 Breast Cancer Cells with PEI-
Enhanced HSA Nanoparticles. Prior to transfecting cells with
nanoparticles, cells were washed with PBS and replenished
with fresh serum-free DMEM. The PEI-coated HSA na-
noparticles were prepared using 5% of Rhodamine-tagged
HSA. The nanoparticles were puriﬁed and added to the cells.
After 8hrs of incubation of cells at 37◦C with the nanopar-
ticles, the culture medium was replaced with fresh DMEM,
containing 10% FBS. Under the ﬂuorescence microscope
(TE2000-U, Nikon; USA), pictures were taken to assess the
levels of transfection. The percentage of transfected cells
was calculated by using the average of the number of cells
exhibiting ﬂuorescence under ﬁve diﬀerent ﬁelds of view.
2.8. Cell Viability Assay. The number of surviving cells
was assessed using the Promega Cell-Titer 96 AQueous
Non-Radioactive Cell Proliferation MTS Assay kit. 3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium, (MTS), and phenazine me-
thosulfate reagents were used. Live cells reduce MTS to form
formazan, a compound soluble in tissue-culture media.
The amount of formazan is proportional to the number
of living cells and can be quantiﬁed by measuring the
absorbance of formazan, using 1420-040 Victor3 Multilabel
Counter (Perkin Elmer, USA) at 490nm. The intensity of the
color produced by formazan indicates the viability of cells.
MCF-7 cells were seeded onto a 96-well plate (104 cells per
well) 24hrs before treatment. Cytotoxicity was measured
at the predetermined time for each experiment using the
MTS assay which was performed as per the manufacturer’s
protocol.
2.9. TUNEL Assay. The DeadEnd Colorimetric TUNEL Sys-
tem detects DNA fragmentation (an indicator of apoptosis)
of each cell undergoing apoptosis. The fragmented ends of
DNA are labelled by a modiﬁed TUNEL (TdT-mediated
dUTP Nick-End Labeling) assay. The terminal deoxynu-
cleotidyl transferase (TdT) enzyme adds a biotinylated
nucleotide at the 3 -OH ends of DNA; the biotinylated
nucleotides are conjugated with horseradish-peroxidase-la-
belled streptavidin. The peroxidase is then detected using
its substrate, hydrogen peroxide, and the chromogen, diam-
inobenzidine (DAB). Following the manufacturer’s protocol,
the nuclei of apoptotic cells are stained brown.
3. Results and Discussion
3.1. Optimizing Coating of Cationic DOX-Loaded PEI-
Enhanced HSA Nanoparticles. The desolvation technique
used to prepare the HSA nanoparticles [22, 27, 30] is simple
to perform; the synthesized particles were consistent in size,
surface zeta potential, and morphology. The desolvation
technique involves a liquid-liquid phase separation of an
aqueous homogenous albumin solution, leading to the for-
mation of a colloidal (or coacervate) phase that contains the
nanoparticles [31]. In addition, the size of the nanoparticles
formed by this technique can be altered based upon the
v a r i o u sp a r a m e t e r so ft h et e c h n i q u e ,s u c ha sc o n c e n t r a t i o n
and pH of HSA solution, volume and rate of ethanol
addition [22, 29, 32]. In our previous research paper, we
presented that the smallest nanoparticle size was achieved
with20mg/mLHSAatpH8.5and ∼1-2mLof100%ethanol
[22] .T h e s ep a r a m e t e r sw e r ek e p tu n c h a n g e di nt h i ss t u d y
as well. Glutaraldehyde cross-linking was carried out to
stabilize the formed HSA nanoparticles before PEI surface
coating; this also increases the drug entrapment ability of the
HSA nanoparticles [3]. The encapsulation eﬃciency of DOX
withinPEI-enhancedHSAnanoparticleswascalculatedtobe
∼88.24 + 2.13%.
In the current study, PEI-enhanced HSA nanoparticles
were prepared by coating the HSA nanoparticles that have
a negative surface charge with electrostatic binding to the
positively charged PEI. As HSA is an acidic protein, it
c a r r i e san e g a t i v ez e t ap o t e n t i a li n∼pH 8.5 and thus
allows the positive PEI to bind to HSA nanoparticles [12,
33, 34]. The amount of PEI used for surface coating of
the nanoparticles was optimized. Table 1 shows that as the
amount of PEI was increased, an increase in the particle size4 Journal of Drug Delivery
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Figure 1: Formation of polyethylenimine- (PEI-) enhanced HSA nanoparticles.
500nm
(a)
20nm
(b)
Figure 2: (a) Transmission electron microscope images of drug-loaded PEI-enhanced HSA nanoparticles. (b) Higher magniﬁcation image
of the nanoparticles.
Table 1: Eﬀect of the amount of PEI added (µgp e rm go fH S A )
on the physical characteristics of drug-loaded PEI-enhanced HSA
nanoparticles prepared at pH 8.5, 20mg/mL HSA (mean ± S.D.,
n = 3).
Amount of PEI (µg)
added per mg of HSA Particle size (nm) Zeta potential (mV)
0 99.63 ± 6.01 −46.9 ± 5.06
10 105.6 ± 8.07 +6.14 ± 1.11
20 121.7 ± 2.78 +12.3 ± 0.18
30 137.2 ± 8.20 +17.92 ± 1.04
40 135.5 ± 4.27 +18.38 ± 3.7
was observed, and the surface zeta potential became positive.
This increase in size was gradual and could be attributed to
the addition of the PEI surface coating or slight aggregation
of the particles. The surface zeta potential increased from
approximately −47 to +18mV, clearly indicating that the
PEI was successfully adsorbed to the nanoparticle surface.
Furthermore, results presented in Table 2 show that 8hrs
of incubation at a stirring speed of 1000rpm resulted in
the smallest particle size and maximum zeta potential.
Table 2:EﬀectofincubationtimeforPEIcoatingandstirringspeed
during the desolvation step on the physical characteristics of drug-
loaded PEI-enhanced HSA nanoparticles, prepared with 20mg/mL
HSA and 30µg of PEI added per mg of HSA (mean ± S.D., n = 3).
Time of
incubation
with PEI (hrs)
Stirring speed
(rpm)
Particle size
(nm)
Zeta potential
(mV)
4
250 412.76 ± 12.7 8.94 ± 0.12
500 248.43 ± 1.7 7.20 ± 0.19
1000 130.47 ± 11.3 4.24 ± 0.08
8
250 362.77 ± 0.65 17.4 ± 0.36
500 218.57 ± 15.9 19.14 ± 0.51
1000 100.73 ± 3.93 18.39 ± 0.27
12
250 332.67 ± 16.2 16.13 ± 0.91
500 205.17 ± 8.16 10.99 ± 0.71
1000 111.53 ± 4.72 13.73 ± 0.36
Conditions were optimized to attain the smallest particle size
and maximum zeta potential in order to achieve the highest
cellular uptake [19]. Size dependence of cellular uptake hasJournal of Drug Delivery 5
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Figure3:CellularuptakeofPEI-enhancednanoparticleswasassessedwithrespecttodiﬀerentamountsofPEIusedforcoating(mean±S.D.,
n = 3).PEI-enhancedHSAnanoparticleswerepreparedusinganethanoldesolvationtechniquewith20mg/mLHSA.Thenanoparticleswere
composed of 5% tetramethylrhodamine-conjugated BSA, and the cellular uptake was observed under a ﬂuorescence microscope (TE2000-
U, Nikon; USA). (a) Percentage of cellular uptake with nanoparticles prepared using 0, 10, 20, and 30µgo fP E Ip e rm go fH S A .V a r y i n g
quantities of nanoparticle preparations were added to the cells: 50, 100, and 200µL. Fluorescence images of cellular uptake of diﬀerent HSA
nanoparticle preparations, consisting of tetramethylrhodamine-conjugated BSA, are shown; (b) uncoated HSA nanoparticles, (c) 10µga n d
(d) 30µg of PEI added per mg of HSA to form PEI-enhanced HSA nanoparticles. Corresponding bright ﬁeld images are illustrated below (e,
f, and g).
been studied previously [35]. For instance, Prabha et al.
showed that smaller nanoparticles (∼70nm) experienced
a 27-fold greater transfection than larger nanoparticles in
COS-7 cell line, with all other parameters kept constant
[35]. Similarly, surface charge of nanoparticles plays an
important role in determining their transfection eﬃciency
[19]. Harush-Frenkel et al. found that cationic nanoparticles
resultedin rapid internalization throughaclathrin-mediated
pathway, while nanoparticles with a negative surface charge
showed less eﬃcient cellular uptake [36]. The TEM images
shown in Figure 2 illustrate roughly spherical shape of the
formed HSA nanoparticles of approximately 100nm of size.
3.2.IncreasedCellularUptakeofPEI-EnhancedHSANanopar-
ticles. The cellular internalization of PEI-enhanced HSA
nanoparticles was assessed by transfecting MCF-7 breast
cancer cells with nanoparticles prepared with Rhodamine-
tagged HSA. As shown in Figure 3, images were taken using6 Journal of Drug Delivery
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Figure 4: : (a) Dose-response cytotoxicity of DOX-loaded PEI-enhanced HSA nanoparticles as compared to free DOX administered to
MCF-7 breast cancer cells in log-phase culture after 48hrs of treatment with diﬀerent concentrations of DOX. (b) Time of exposure:
cytotoxicity resulting from DOX-loaded PEI-enhanced HSA nanoparticles versus free DOX over 96hrs was measured. The concentration of
DOX administered was 1µg/mL to MCF-7 breast cancer cells. Percentage of viable cells was assessed by an MTS assay and then compared to
untreated cells in the control wells (mean ± S.D., n = 3).
a ﬂuorescence microscope (TE2000-U, Nikon; USA). Cell
transfection was measured with respect to the amount of PEI
added to coat the nanoparticles. It is essential to optimize
the amount of PEI used for coating the nanoparticles as
this helps determine how much of the polymer is required
to reach the maximum adsorption capacity of the surface
of the nanoparticles and their corresponding surface zeta
potential. Firstly, the lowest percentage of cell transfection
was observed with uncoated nanoparticles, which can be
attributed to the negative surface zeta potential of the
uncoated HSA nanoparticles. Based on Figure 3(a),i tc a nb e
concluded that increasing the amount of PEI, up to 20µg
of PEI per mg of HSA, used for coating the nanoparticles
leads to an increase in cell transfection. Further increasing
the amount of PEI used for coating the nanoparticles did not
translate into higher transfection eﬃciency. This observation
couldbeexplainedbyreachingthemaximumcapacityofPEI
binding with the surface of HSA nanoparticles. Figures 3(b),
3(c),a n d3(d) show corresponding ﬂuorescence images of
cellular uptake of PEI-enhanced HSA nanoparticles. The in-
crease in cell transfection due to coating the nanoparticles
with PEI is in agreement with previously published results.
Cationic nanoparticles are shown to bind the negatively
charged functional groups, such as sialic acid, found on cell
surfaces and initiate transcytosis [19]. PEI-based nanopar-
ticles have shown increased cellular uptake of siRNA. In
vivo administration of siRNA delivered using PEI-based
nanoparticles resulted in 80% decrease in the target gene
expression; however, cytotoxicity was a concern [37, 38].
Therefore, a reasonable conclusion to draw from the results
of the cell transfection experiment would be that the PEI
adsorbed to the surface of the nanoparticles aids in the
internalization of the particles.
3.3. DOX Delivery with PEI-Enhanced HSA Nanoparticles
to Kill Breast Cancer Cells. The eﬃcacy of anti-cancer
chemotherapy is limited by the cytotoxic eﬀect on healthy
cells due to a lack of selectivity of the drugs and poor uptake
of the therapeutics by the tumor cells [19, 39, 40]. Dox-
orubicin, a strong antineoplastic agent, has been shown to
cause irreversible cardiomyopathy, which could also lead to
congestive heart failure [1, 19, 40]. In order to overcome
this issue, many researchers have tried delivering DOX by
nanoparticles that reduce the amount of drug reaching
cardiac tissue while increasing the accumulation of the drug-
loaded nanoparticles in the tumor tissue [7, 9, 32, 41–
43]. Furthermore, by incorporating a layer of PEI on the
surface of the HSA nanoparticles, we aimed to increase their
cellular uptake in the tumor tissue. Previously, uncoated
HSA nanoparticles were studied for the delivery of DOX
to neuroblastoma cell lines. Results suggested that DOX
delivered using nanoparticles was more cytotoxic against
cancer cells as compared to free DOX. In our study, we
observed that the cytotoxicity of DOX-loaded nanoparticle
and free DOX against MCF-7 breast cancer cells was
about the same after 48hrs as the DOX concentration
was increased, shown in Figure 4(a). However, assessing the
cytotoxicity at diﬀerent time points in Figure 4(b) showed
that DOX-loaded nanoparticles led to a greater decrease in
cell viability as compared to free DOX after 144hrs. This
observation can be explained by the slow release of DOX
fromthenanoparticles.Theseresultswouldbemoreeﬀective
in vivo as the free drug would diﬀuse out of the tumor
tissue, while the nanoparticles would accumulate within the
tumor tissue due to the EPR eﬀect and release the drug
over time. Images of treated cells after TUNEL staining
in Figures 5(a), 5(b),a n d5(c) conﬁrm that the cytotoxic
eﬀect of DOX-loaded nanoparticles was comparable to free
DOX. Figure 5(c) shows that the cells remained healthy and
viableaftertheadditionofPEI-enhancedHSAnanoparticles,
suggesting that the nanoparticle formulation does not have
cytotoxic eﬀects.Journal of Drug Delivery 7
100µm
(a) DOX-NPs
100µm
(b) Free DOX (c) Empty NPs
Figure 5: TUNEL assay to conﬁrm cell death after DOX administration (24hrs): (a) DOX-loaded PEI-enhanced HSA nanoparticles, (b) free
DOX, and (c) empty PEI-enhanced HSA nanoparticles. The concentration of DOX administered was 1µg/mL to MCF-7 breast cancer cells
grown in a 96-well plate. The black arrows point towards cells showing TUNEL staining.
4. Conclusion
In our current study, we used modiﬁed HSA nanoparticles
by adding an outer coating of the polyethylenimine (PEI) to
improvethetherapeuticindexofdoxorubicinagainstMCF-7
breast cancer cells. The nanoparticles prepared were charac-
terized based upon size and surface charge with respect to
the amount of PEI used for coating. A rise in the surface
zeta potential of the nanoparticles conﬁrms the electrostatic
binding of PEI with the surface of HSA nanoparticles.
Diﬀerent microscopic techniques were employed to observe
the shape, dispersion, and morphology of the nanoparticles.
PEI-enhanced HSA nanoparticles resulted in a higher cell
transfection percentage, indicating that the addition of the
layer of cationic polymer did improve cell penetration of
the particles. PEI-enhanced HSA nanoparticles illustrated a
more potent cytotoxic eﬀect on MCF-7 breast cancer cells
over longer time duration. The results shown in this study
are promising and set a platform for further examining the
suitability of this PEI-enhanced delivery system in vivo.
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